A multicentre, observational, postmarketing study of pazopanib in patients with metastatic soft tissue sarcoma in Japan
Latest Information Update: 28 Apr 2021
At a glance
- Drugs Pazopanib (Primary)
- Indications Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 28 Apr 2021 New trial record
- 01 Apr 2021 Results (n=680) published in the Japanese Journal of Clinical Oncology